Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 7/20 | 0.72 |
| ▸ | ECE1 | P42892 | 1/20 | 0.72 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.72 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.71 |
| ▸ | GHSR | Q92847 | 4/20 | 0.70 |
| ▸ | NPY2R | P49146 | 4/20 | 0.70 |
| ▸ | PTH1R | Q03431 | 3/20 | 0.70 |
| ▸ | CCKBR | P32239 | 1/20 | 0.70 |
| ▸ | NPY1R | P25929 | 1/20 | 0.66 |
| ▸ | NPY4R | P50391 | 1/20 | 0.66 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.66 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29694495 | 0.94 | PTH1R (0.78) | GLP1RECE1MUS81NR3C1PTH1R | |
| SCHEMBL30683162 | 0.93 | GLP1R (0.81) | GLP1RECE1MUS81NR3C1GHSR | |
| SCHEMBL29395456 | 0.91 | GLP1R (0.78) | GLP1RECE1MUS81NR3C1GHSR | |
| SCHEMBL30623138 | 0.90 | GLP1R (0.74) | GLP1RECE1MUS81NR3C1GHSR | |
| SCHEMBL29477246 | 0.90 | GLP1R (0.73) | GLP1RECE1MUS81NR3C1GHSR | |
| SCHEMBL29383537 | 0.90 | GLP1R (0.74) | GLP1RECE1MUS81NR3C1GHSR | |
| SCHEMBL29357856 | 0.90 | GLP1R (0.77) | GLP1RECE1MUS81NR3C1GHSR | |
| SCHEMBL30285498 | 0.90 | PTH1R (0.74) | GLP1RNR3C1GHSRNPY2RPTH1R | |
| SCHEMBL29829645 | 0.89 | GLP1R (0.75) | GLP1RECE1MUS81NR3C1GHSR | |
| SCHEMBL31060658 | 0.89 | GLP1R (0.89) | GLP1RECE1MUS81NR3C1PTH1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119799647-A | Cell for recoding early termination codon and application thereof | 北京医院 | 2025-04-11 | — | — | CN | claimed |
| CN-117757870-A | Method for preparing reducing sugar by multienzyme cooperation | 中国农业科学院农产品加工研究所 | 2024-03-26 | — | — | CN | claimed |
| WO-2025201243-A1 | RECOMBINANT RESPIRATORY SYNCYTIAL VIRUS PRE-FUSION (F) PROTEIN MUTANT AND USE THEREOF | 中国医学科学院医学生物学研究所 | 2025-10-02 | — | — | WO | disclosed |
| US-12415835-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-16 | — | — | US | disclosed |
| CN-119638825-B | Shark nanobody targeting infectious subcutaneous and hematopoietic tissue necrosis virus of prawns and preparation method thereof | 中国海洋大学三亚海洋研究院 | 2025-04-11 | — | — | CN | disclosed |
| CN-119799647-A | Cell for recoding early termination codon and application thereof | 北京医院 | 2025-04-11 | — | — | CN | disclosed |
| CN-119638825-A | Shark nanobody targeting infectious subcutaneous and hematopoietic tissue necrosis virus of prawns and preparation method thereof | 中国海洋大学三亚海洋研究院 | 2025-03-18 | — | — | CN | disclosed |
| CN-119286772-B | In-vitro proliferation method for myoblasts of marine fishes | 中国海洋大学三亚海洋研究院 | 2025-02-25 | — | — | CN | disclosed |
| WO-2025025808-A1 | CAS PROTEIN, CORRESPONDING GENE EDITING SYSTEM, AND USE | 尧唐(上海)生物科技有限公司 | 2025-02-06 | — | — | WO | disclosed |
| CN-119286772-A | In-vitro proliferation method for myoblasts of marine fishes | 中国海洋大学三亚海洋研究院 | 2025-01-10 | — | — | CN | disclosed |
| WO-2024240053-A1 | GENE EDITING PROTEIN, CORRESPONDING GENE EDITING SYSTEM THEREOF, AND USE THEREOF | 尧唐(上海)生物科技有限公司 | 2024-11-28 | — | — | WO | disclosed |
| WO-2023179795-A1 | METHOD FOR RAPIDLY, SIMPLY AND CONVENIENTLY OBTAINING CORRECTLY PAIRED TCRS, AND OBTAINED TCRS | 立凌生物制药(苏州)有限公司 | 2023-09-28 | — | — | WO | disclosed |
| CN-115807040-A | PD-1 protein expression vector and application thereof | 上海澳斯康生物制药有限公司 | 2023-03-17 | — | — | CN | disclosed |
| WO-2022218339-A1 | RECOMBINANT NEWCASTLE DISEASE VIRUS RNDV-OX40L, GENOME THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | 江苏康缘瑞翱生物医药科技有限公司 | 2022-10-20 | — | — | WO | disclosed |
| WO-2022218340-A1 | RECOMBINANT NEWCASTLE DISEASE VIRUS RNDV-VEGF-TRAP, GENOME THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | 江苏康缘瑞翱生物医药科技有限公司 | 2022-10-20 | — | — | WO | disclosed |
| CN-114958637-A | Engineering bacterium for producing beta-eudesmol and construction method and application thereof | 滨州医学院 | 2022-08-30 | — | — | CN | disclosed |
| CN-114891779-A | Detection method for cloned TCR sequence and application thereof | 立凌生物制药(苏州)有限公司 | 2022-08-12 | — | — | CN | disclosed |
| CN-114854751-A | Metabolic engineering method, squalene-producing engineering bacterium, nerolidol-producing engineering bacterium, and construction method and application thereof | 滨州医学院 | 2022-08-05 | — | — | CN | disclosed |
| CN-114645075-A | Detection method of true gene variation | 上海韦翰斯生物医药科技有限公司 | 2022-06-21 | — | — | CN | disclosed |
| CN-113512552-B | Two-chamber gene BjMc2 and three-chamber gene Bjmc2 related to multi-chamber characters of mustard type rape and application thereof | 华中农业大学 | 2022-05-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12415835-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | GLP1R 3/4885ECE1 1188/4885MUS81 1784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.